These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 21935577)

  • 21. Pharmacokinetics and antitumor efficacy of XMT-1001, a novel, polymeric topoisomerase I inhibitor, in mice bearing HT-29 human colon carcinoma xenografts.
    Walsh MD; Hanna SK; Sen J; Rawal S; Cabral CB; Yurkovetskiy AV; Fram RJ; Lowinger TB; Zamboni WC
    Clin Cancer Res; 2012 May; 18(9):2591-602. PubMed ID: 22392910
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antitumor activity of HER1/EGFR tyrosine kinase inhibitor erlotinib, alone and in combination with CPT-11 (irinotecan) in human colorectal cancer xenograft models.
    Chen J; Smith M; Kolinsky K; Adames V; Mehta N; Fritzky L; Rashed M; Wheeldon E; Linn M; Higgins B
    Cancer Chemother Pharmacol; 2007 Apr; 59(5):651-9. PubMed ID: 16937104
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts.
    Prewett MC; Hooper AT; Bassi R; Ellis LM; Waksal HW; Hicklin DJ
    Clin Cancer Res; 2002 May; 8(5):994-1003. PubMed ID: 12006511
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Detailed distribution of NK012, an SN-38-incorporating micelle, in the liver and its potent antitumor effects in mice bearing liver metastases.
    Takahashi A; Ohkohchi N; Yasunaga M; Kuroda J; Koga Y; Kenmotsu H; Kinoshita T; Matsumura Y
    Clin Cancer Res; 2010 Oct; 16(19):4822-31. PubMed ID: 20807756
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The antitumor activity of NK012, an SN-38-incorporating micelle, in combination with bevacizumab against lung cancer xenografts.
    Kenmotsu H; Yasunaga M; Goto K; Nagano T; Kuroda J; Koga Y; Takahashi A; Nishiwaki Y; Matsumura Y
    Cancer; 2010 Oct; 116(19):4597-604. PubMed ID: 20572031
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Activity of MM-398, nanoliposomal irinotecan (nal-IRI), in Ewing's family tumor xenografts is associated with high exposure of tumor to drug and high SLFN11 expression.
    Kang MH; Wang J; Makena MR; Lee JS; Paz N; Hall CP; Song MM; Calderon RI; Cruz RE; Hindle A; Ko W; Fitzgerald JB; Drummond DC; Triche TJ; Reynolds CP
    Clin Cancer Res; 2015 Mar; 21(5):1139-50. PubMed ID: 25733708
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy.
    Drummond DC; Noble CO; Guo Z; Hong K; Park JW; Kirpotin DB
    Cancer Res; 2006 Mar; 66(6):3271-7. PubMed ID: 16540680
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Stable Irinotecan Liposome with Enhanced Antitumor Activity in a Range of Tumor Models.
    Su Z; Li L; Hao F; Zhao J; Li M; Zhao X; Zhao D
    Pharm Res; 2023 Dec; 40(12):3043-3058. PubMed ID: 37914843
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics and biodistribution of the camptothecin-polymer conjugate IT-101 in rats and tumor-bearing mice.
    Schluep T; Cheng J; Khin KT; Davis ME
    Cancer Chemother Pharmacol; 2006 May; 57(5):654-62. PubMed ID: 16133526
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks.
    Rowinsky EK; Grochow LB; Ettinger DS; Sartorius SE; Lubejko BG; Chen TL; Rock MK; Donehower RC
    Cancer Res; 1994 Jan; 54(2):427-36. PubMed ID: 8275479
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synthesis and in vivo antitumor efficacy of PEGylated poly(l-lysine) dendrimer-camptothecin conjugates.
    Fox ME; Guillaudeu S; Fréchet JM; Jerger K; Macaraeg N; Szoka FC
    Mol Pharm; 2009; 6(5):1562-72. PubMed ID: 19588994
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nonclinical pharmacokinetics and activity of etirinotecan pegol (NKTR-102), a long-acting topoisomerase 1 inhibitor, in multiple cancer models.
    Hoch U; Staschen CM; Johnson RK; Eldon MA
    Cancer Chemother Pharmacol; 2014 Dec; 74(6):1125-37. PubMed ID: 25228368
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preclinical activity of nanoliposomal irinotecan is governed by tumor deposition and intratumor prodrug conversion.
    Kalra AV; Kim J; Klinz SG; Paz N; Cain J; Drummond DC; Nielsen UB; Fitzgerald JB
    Cancer Res; 2014 Dec; 74(23):7003-13. PubMed ID: 25273092
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cell kinetics-dependent antitumor effect of irinotecan hydrochloride induced by the synchronizing effect of hydroxyurea: cell kinetics and dosing time.
    Akagi T; Ushinohama K; Kage Y; Ishizaki T; Makinosumi T; Yamauchi A; Taguchi Y; Inoue K; Yukawa E; Higuchi S; Ohdo S
    Life Sci; 2003 Jan; 72(10):1183-97. PubMed ID: 12505548
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effective irinotecan (CPT-11)-containing liposomes: intraliposomal conversion to the active metabolite SN-38.
    Sadzuka Y; Hirotsu S; Hirota S
    Jpn J Cancer Res; 1999 Feb; 90(2):226-32. PubMed ID: 10189894
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enhanced antitumor activity of 6-hydroxymethylacylfulvene in combination with irinotecan and 5-fluorouracil in the HT29 human colon tumor xenograft model.
    Britten CD; Hilsenbeck SG; Eckhardt SG; Marty J; Mangold G; MacDonald JR; Rowinsky EK; Von Hoff DD; Weitman S
    Cancer Res; 1999 Mar; 59(5):1049-53. PubMed ID: 10070962
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effective conversion of irinotecan to SN-38 after intratumoral drug delivery to an intracranial murine glioma model in vivo. Laboratory investigation.
    Wang W; Ghandi A; Liebes L; Louie SG; Hofman FM; Schönthal AH; Chen TC
    J Neurosurg; 2011 Mar; 114(3):689-94. PubMed ID: 20415520
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Marked antitumor activity of a new potent acronycine derivative in orthotopic models of human solid tumors.
    Guilbaud N; Kraus-Berthier L; Meyer-Losic F; Malivet V; Chacun C; Jan M; Tillequin F; Michel S; Koch M; Pfeiffer B; Atassi G; Hickman J; Pierré A
    Clin Cancer Res; 2001 Aug; 7(8):2573-80. PubMed ID: 11489841
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Optimal dosing schedule in combination therapy with irinotecan and doxifluridine in a human colorectal cancer xenograft model].
    Yanagisawa M; Ishikawa T; Ouchi KF; Tanaka Y
    Gan To Kagaku Ryoho; 2003 Feb; 30(2):223-30. PubMed ID: 12610870
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preclinical evaluation of CPT-11 and its active metabolite SN-38.
    Lavelle F; Bissery MC; André S; Roquet F; Riou JF
    Semin Oncol; 1996 Feb; 23(1 Suppl 3):11-20. PubMed ID: 8633248
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.